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Abstract
The clinical relevance of Acinetobacter species, other than A. baumannii, as human pathogens has not been sufﬁciently assessed owing to the
insufﬁciency of simple phenotypic clinical diagnostic laboratory tests. Infections caused by these organisms have different impacts on clinical
outcome and require different treatment and management approaches. It is therefore important to correctly identify Acinetobacter species.
Matrix-assisted laser desorption ionization–time of ﬂight mass spectrometry (MALDI-TOF MS) has been introduced to identify a wide range
of microorganisms in clinical laboratories, but only a few studies have examined its utility for identifying Acinetobacter species, particularly
those of the non-Acinetobacter baumannii complex. We therefore evaluated MALDI-TOF MS for identiﬁcation of Acinetobacter species by
comparing it with sequence analysis of rpoB using 123 isolates of Acinetobacter species from blood. Of the isolates examined, we identiﬁed
106/123 (86.2%) to species, and 16/123 (13.0%) could only be identiﬁed as acinetobacters. The identity of one isolate could not be
established. Of the 106 species identiﬁed, 89/106 (84.0%) were conﬁrmed by rpoB sequence analysis, and 17/106 (16.0%) were discordant.
These data indicate correct identiﬁcation of 89/123 (72.4%) isolates. Surprisingly, all blood culture isolates were identiﬁed as 13 species of
Acinetobacter, and the incidence of Acinetobacter pittii was unexpectedly high (42/123; 34.1%) and exceeded that of A. baumannii (22/123;
17.9%). Although the present identiﬁcation rate using MALDI-TOF MS is not acceptable for species-level identiﬁcation of Acinetobacter,
further expansion of the database should remedy this situation.
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Introduction
The genus Acinetobacter comprises 30 named and nine genomic
species [1,2]. Its most clinically important representative,
A. baumannii, has emerged as one of the most problematic
pathogens for healthcare institutions worldwide because of its
resistance to several antibiotics [1,3]. Phenotypic tests only
identify members of the Acinetobacter calcoaceticus–A. bauman-
nii complex [4–7], in contrast, several molecular methods are
more effective. Among these, ampliﬁed 16S rRNA gene
restriction analysis, ampliﬁed fragment length polymorphism
and 16S rRNA and RNA polymerase b-subunit (rpoB) gene
sequence analyses are most frequently used [1,8]. The most
effective technique may be rpoB gene sequence analysis
because of abundant rpoB polymorphisms [9], and it has
facilitated species identiﬁcation [8,9]. Species other than
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A. baumannii, such as Acinetobacter pittii, Acinetobacter nosocom-
ialis, Acinetobacter ursingii and Acinetobacter haemolyticus, are
also important nosocomial pathogens [4,7,10,11].
Carbapenems play an important role in treating Acinetobacter
infections; however, carbapenem-resistant and multidrug-resis-
tant A. baumannii strains have spread worldwide in the past two
decades [3]. The expression of OXA-type class D carbapene-
mases, which are endogenous or acquired, is activated by
promoter sequences located within ISAba insertion sequences
[12,13]. Metallo-b-lactamases (MBLs) also confer carbapenem
resistance. The blaIMP-1 gene, which encodes an MBL, was
frequently detected in carbapenem-resistant non-A. baumannii
isolates [14–16]. The b-lactamases act synergistically with other
mechanisms of drug resistance, including alteration of drug
permeability and efﬂux pumps. Colistin is useful for treating
A. baumannii infections as well, and most Acinetobacter species
are susceptible to it. However, Acinetobacter genomic species
13BJ is intrinsically colistin resistant [4,17].
Although molecular genetic methods identify Acinetobacter
species, they are typically too labour-intensive for use in clinical
laboratories. Matrix-assisted laser desorption ionization–time
of ﬂight mass spectrometry (MALDI-TOF MS) is increasingly
used to identify a wide range of microorganisms in clinical
laboratories, including Gram-positive and Gram-negative bac-
teria, yeasts and even ﬁlamentous fungi [18]. It is a rapid and
inexpensive alternative to molecular genetic identiﬁcation and
offers equivalent accuracy [19]. Moreover, complete bacterial
identiﬁcation using MALDI-TOF MS is more cost-effective than
conventional methods [20,21]. Nevertheless, some non-
fermentingGram-negative bacilli, including Acinetobacter species,
have been misidentiﬁed because of an incomplete database [19].
Further, few published studies are available regarding the
application of MALDI-TOF MS to Acinetobacter species.
Therefore, the purpose of the present study was to evaluate
the ability of MALDI-TOF MS to identify Acinetobacter species.
We report here a comparison of MALDI-TOF MS with rpoB
sequence analysis of Acinetobacter strains isolated from blood
cultures.
Materials and Methods
Bacterial isolates
This study included 123 consecutive blood culture isolates of
Acinetobacter species collected between April 2003 and March
2011 from 123 patients in two University Hospitals in Japan.
Isolates were routinely identiﬁed as Acinetobacter species using
phenotypicmethods, theMicroscanWalkaway System (Siemens
Healthcare Diagnostics Japan, Tokyo, Japan) and the Vitek 2
System (Sysmex-bioMerieux Japan, Kobe, Japan). The 16 type
and reference strains of Acinetobacter used in this study were as
follows: A. baumannii ATCC17978, A. baylyi KCTC12413T,
A. bereziniae LMG1003T, A. calcoaceticus KCTC2357T, A. guillo-
uiae LMG988T, A. grimontiiKCTC12416T, A. juniiKCTC12406T,
A. johnsonii KCTC12405T, A. lwofﬁi KCTC12407T, A. nosocomi-
alis LMG10619T, A. oleivoransKCTC23045T, A. pittii LMG1035T,
A. radioresistens NBRC102413T, A. soli KCTC22184T, A. ursingii
KCTC12410T and Acinetobacter gen. sp. 14BJ LMG10627. All
strains were stored at 80°C, precultured for 12–24 h,
and cultured aerobically overnight on 5% sheep blood agar at
37°C.
Identiﬁcation of Acinetobacter species
Species identiﬁcation of isolates was performed by partial
sequence analysis of rpoB, using the primers Ac696F and
Ac1093R [8]. All isolates were considered correctly identiﬁed
when the rpoB sequence yielded ≥98% identity with the closest
species sequence match in the GenBank database. Identiﬁca-
tion of A. baumannii was conﬁrmed by PCR ampliﬁcation of
blaOXA-51-like [12]. A neighbour-joining (NJ) tree was con-
structed using the MEGA software, version 5 [22].
MALDI–TOF MS
Strains were extracted as described [18]. A sample of each
colony was suspended in 300 lL distilled water and adjusted to
McFarland standard 2, and 900 lL absolute ethanol was added.
The suspension was vortexed vigorously and centrifuged at
20 000 g for 5 min. The supernatant was discarded, and the
pellet was dried at 55°C for at least 30 min. Ten microlitres of
70% formic acid (Wako Pure Chemical Industries, Osaka, Japan)
was then added and thoroughly mixed by pipetting. Next, 10 lL
of acetonitrile (Wako) was added, and the sample was centri-
fuged again at 20 000 g for 5 min, and then 1 lL of supernatant
was placed onto a stainless steel target plate (Bruker Daltonik
GmbH, Lepizig, Germany) and dried for c.10 min at room
temperature. Finally, 1.5 lL of matrix solution, comprising a
saturated solution of a-cyano-4-hydrocinnamic acid (Bruker
Daltonik) in 50% acetonitrile and 2.5% triﬂuoroacetic acid
(Wako), was applied to the samples and co-crystallized at room
temperature for 10 min.
The samples prepared using the standard extraction
method described above were applied to a MicroFlex LT
mass spectrometer (Bruker Daltonik). Each measurement was
performed once for each culture. Escherichia coli DH5a was
used as a quality control for each experiment, as recom-
mended by the manufacturer.
Data analysis
The log score identiﬁcation criteria recommended by the
manufacturer (Bruker Daltonik) were used as follows: ≥2.300,
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reliable species; 2.00–2.299, probable species; 1.700–1.999,
genus; and <1.700, unreliable. Duplicate experiments were
performed. For identifying genus and species, the least
stringent identiﬁcation criterion was used. If the genus of
one strain was identiﬁed in the ﬁrst experiment and the
species in the second, the genus was used for analysis. If the
results of two experiments were different, such as genus or
unreliable identiﬁcation, the unreliable identiﬁcation result was
used. A dendrogram was constructed using the correlation
distance measure and the average linkage algorithm settings of
the BIOTYPER 3.0 software (Bruker Daltonik).
Results
Identiﬁcation of Acinetobacter species
Thirteen species were identiﬁed according to rpoB sequence
analysis (Table 1). The identities of the 123 isolates were as
follows: A. pittii (n = 42); A. baumannii (n = 22); A. nosocomialis
(n = 19); A. ursingii (n = 15); A. grimontii (n = 8); A. oleivorans
(n = 4); A. bereziniae (n = 2); A. soli (n = 2); A. johnsonii (n = 1);
A. junii (n = 1); A. baylyi (n = 1); A. radioresistens (n = 1); and
Acinetobacter gen. sp. 14BJ (n = 1). The sequences of four
strains were <98% identical to the rpoB sequence of any species
in the GenBank database and could not be reliably identiﬁed; of
these four strains, three strains were 96% identical and one
strain was 97% identical to the rpoB sequence of A. baumannii.
The dendrogram indicated that these four strains comprise a
cluster, which is closely related to a cluster represented by
A. nosocomialis: LMG10619 (Fig. 1). Further analysis of these
four isolates is planned. PCR analysis detected the blaOXA-51-like
gene in 22 of the A. baumannii strains; PCR analysis of the other
101 strains failed to detect a product (Table 1).
MALDI-TOF MS
MALDI-TOF MS analyses yielded scores of v ≥2.3, 53/123
(43.1%); 2.00 ≤ v < 2.3, 53/123 (43.1%); 1.7 ≤ v < 2, 16/123
(13.0%); and v < 1.7, 1/123 (0.8%) for reliable species, probable
species, genus and unreliable identiﬁcations, respectively. Based
on their rpoB sequences, 106 isolates with scores v ≥2.0, 89/106
(84.0%) were conﬁrmed at the species level and 17/106 (16.0%)
were not (Table 1). Hence, species identiﬁcation of 89/123
(72.4%) was achieved. Interestingly, seven of the 16 uncon-
ﬁrmed results scoring 1.7 ≤ v < 2 were conﬁrmed by their
rpoB sequences. Therefore, the overall level of concordance
between MALDI-TOF MS (valid and invalid results) and rpoB
sequence analysis at the species level was 78.0% (96/123).
Among the 17 discordant results for species, the three
isolates identiﬁed as A. baumannii by MALDI-TOF MS, in which
blaOXA-51-like sequences were undetectable, were identiﬁed as
A. nosocomialis according to rpoB sequence analysis. The eight
isolates identiﬁed as A. junii by MALDI-TOF MS were identiﬁed
instead as A. grimontii isolates according to their rpoB
sequences. This discrepancy may be attributed to the synon-
ymy of A. grimontii and A. junii [23]. Sequence analysis of rpoB
revealed that the isolates of A. guillouiae and A. baylyi (one
each) were actually A. bereziniae and A. soli, respectively. This
discrepancy was caused their absence from the database.
A dendrogram was created using the 123 isolates and 16
reference strains (Fig. 2). Three A. nosocomialis isolates erro-
neously identiﬁed as A. baumannii with scores of v ≥2.0 by
MALDI-TOF MS cluster with A. nosocomialis LMG10619. This
cluster includes two A. nosocomialis isolates erroneously iden-
tiﬁed as A. baumannii (MALDI-TOF MS scores, 1.7 ≤ v < 2).
These erroneous identiﬁcations were caused by inaccurate
taxonomic assignment of the given spectra within the Bruker
database. One A. baylyi isolate erroneously identiﬁed as
A. guillouiae clusters with reference strains A. guillouiae
LMG988 and A. bereziniae LMG1003. Acinetobacter baylyi is
known to be transformable by DNA from other Acinetobacter
species [24]. In some cases, it has picked up the rpoB gene from
A. guillouiae [24]. These intragenic recombination events may
have caused this erroneous identiﬁcation. Four isolates, which
were not reliably identiﬁed by rpoB sequence analysis,
represent a cluster with no reference strain. Two were
identiﬁed as A. baumannii (MALDI-TOF MS, v ≥2.0) and the
others as A. baumannii (1.7 ≤v < 2).
TABLE 1. Matrix-assisted laser desorption ionization–time
of ﬂight mass spectrometry (MALDI-TOF) identiﬁcation of
the 123 isolates from patients’ blood samples, showing scores
rpoB (zone l)
sequencing
MALDI-TOF
identiﬁcation Score value
Number
of isolates blaOXA-51
A. pittii (n = 42) A. pittii ≥2.00 37 (21)a 
1.700–1.999 5
A. baumannii
(n = 22)
A. baumannii ≥2.00 21 (10) +
1.700–1.999 1
A. nosocomialis
(n = 20)
A. nosocomialis ≥2.00 14 (9) 
A. baumannii ≥2.00 3 (2)
1.700–1.999 2
A. ursingii (n = 15) A. ursingii ≥2.00 14 (2) 
1.700–1.999 1
A. grimontii (n = 8) A. junii ≥2.00 8 (6) 
A. oleivorans (n = 4) A. calcoaceticus 1.700–1.999 3 
A. pittii 1.700–1.999 1
A. bereziniae (n = 2) A. guillouiae ≥2.00 1 (0) 
1.700–1.999 1
A. soli (n = 2) A. baylyi ≥2.00 1 (0) 
1.700–1.999 1
A. johnsonii (n = l) A. johnsonii ≥2.00 1 (1) 
A. junii (n = l) A. junii ≥2.00 1 (0) 
A. baylyi (n = l) A. guillouiae ≥2.00 1 (1) 
A. radioresistens
(n = l)
A. radioresistens ≥2.00 1 (1) 
Acinetobacter gen.
sp. 14BJ (n = l)
Not reliable
identiﬁcation
<1.700 1 
Not reliable
identiﬁcation
(n = 4)
A. baumannii ≥2.00 3 (0) 
1.700–1.999 1
aThe number of isolates with score ≥2.3.
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A. baumannii
Not reliable identification
A. nosocomialis
A. pittii
A. oleivorans
A. baylyi
A. soli
A. radioresistens
A. ursingii
A. grimontii
A. juniii
Acinetobacter gen.sp.14BJ
A. johnsonii
A. bereziniae
A. baumannii-t22
A. baumannii-d44, d48
A. baumannii-d50
A. baumannii-d9, d18
A. baumannii-d21
A. baumannii-d42
A. baumannii-t23 
A. baumannii-d46
A. baumannii-t9,t39
A. baumannii-d12
A. baumannii-d37
A. baumannii-d38
A. baumannii-ATCC17978
A. baumannii-d8
A. baumannii-d25
A. baumannii-d1
A. baumannii-d23
A. baumannii-t4 
A. baumannii-t25
A. baumannii-t14 
Not reliable identification-d11
Not reliable identification-d13, d15
Not reliable identification-d49
A. nosocomialis-t15 
A. nosocomialis-LMG10619
A. nosocomialis-d26
A. nosocomialis-d41
A. nosocomialis-d14
A. nosocomialis-d35
A. nosocomialis-d47
A. nosocomialis-t5 
A. nosocomialis-t8
A.nosocomialis-t20
A. nosocomialis-t2
A. nosocomialis-t19 
A. nosocomialis-t6,t11, t24
A. nosocomialis-t13 
A. nosocomialis-t3, t16, t21
A. nosocomialis-t27 
A. pittii-t10 
A. pittii-LMG1035
A. pittii-d20
A. pittii-t49 
A. pittii-d2
A. pittii-d6, d10, d16, d19, d29, t1, t18
A. pittii-d7
A. pittii-d40
A .pittii-d32
A. pittii-d36, t29, t30, t31, t32, t33, t34, t37, t38, t40, t41, t46
A. pittii-t47
A. pittii-d5
A. pittii-d52
A. pittii-t7 
A. pittii-d17
A. pittii-t35, t42, t44, d30
A. pittii-d33
A. pittii-d31
A. pittii-t26
A. pittii-d39, d43, d45, t28
A. calcoaceticus-KCTC2357
A. oleivorans-d24
A. oleivorans-KCTC23045
A. oleivorans-d28
A. oleivorans-t48
A. oleivorans-d3
A. lwoffii-KCTC12407
A. baylyi-KCTC12413
A. baylyi-d58
A. guilouiae-LMG988
A. bereziniae-d27
A. bereziniae-LMG1003
A. bereziniae-d51
A. johnsonii-KCTC12405
A. johnsonii-d69
Acinetobacter gen.sp.14BJ-LMG10627
Acinetobacter gen.sp.14BJ-d34
A. junii-KCTC12406
A. juniii-d62
A. grimontii-KCTC12416
A. grimontii-d64
A. grimontii-t52
A. grimontii-t54
A. grimontii-t55
A. grimontii-t17
A. grimontii-d63
A. grimontii-d65
A. grimontii-d59
A. ursingii-t51 
A. ursingii-t56 
A. ursingii-t50
A. ursingii-d71
A. ursingii-d66
A. ursingii-d67
A. ursingii-d57
A. ursingii-d70, t53
A. ursingii-d54
A. ursingii-d61
A. ursingii-d56
A. ursingii-KCTC12410
A. ursingii-d60
A. ursingii-d53
A. ursingii-d72
A. radioresistens-NBRC102413
A. radioresistens-d55
A.  soli-KCTC22184
A. soli-d4
A. soli-d22
100
90
100
65
100
59
93
63
62
62
56
100
69
100
100
100
95
75
60
89
68
75
100
73
55
61
91
98
57
98
99
66
55
55
77
58
91
99
0.02
FIG. 1. Dendrogram generated from partial rpoB sequences for all isolates and reference strains. The scale bar indicates a genetic distance of 0.02,
and the numbers shown next to each node represent bootstrap values (1000 replicates). The strain numbers next to a species name indicate that
sequence types of the isolates with those strain numbers are identical to that of the species.
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FIG. 2. Dendrogram generated using the matrix-assisted laser desorption ionization–time of ﬂight mass spectrometry (MALDI-TOF MS) -speciﬁc
protein signatures for all isolates and reference strains from the MALDI BIOTYPER 3.0 database. The species names in parentheses indicate
identiﬁcations that are discordant with the rpoB sequence. Distance values are relative and normalized to a maximum value of 1000. ▲ indicates a
score of 1.7 ≤v < 2 (genus identiﬁcation) and ● indicates a score of v <1.7.
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Discussion
MALDI-TOF MS is a promising clinical microbiological labora-
tory technique that can rapidly identify a wide range of
bacterial and fungal species [18,19]. MALDI-TOF MS correctly
identiﬁes the species of 85% of routine clinical isolates [19]. In
the present study, however, valid species identiﬁcation was
achieved for only 89/123 (72.4%) of the isolates. Discordant
results at the species level were obtained for 17/123 (13.8%) of
the isolates and were mainly caused by recent changes in the
taxonomy of a given species, the absence of the species name,
or inaccurate taxonomic assignment of a given spectrum in the
MALDI-TOF MS database. These taxonomic discordances
were corrected by updating the database.
We selected 16 type and reference strains for the present
study to create a set of reference spectra to complement the
MALDI-TOF MS database, and spectra from 123 isolates were
reanalysed using the local database. Hence, the original
sensitivity was improved from 74.8% to 82.4% (Table 2). This
update improved identiﬁcation of genus (16/123, 13.0%) as
well. Speciﬁcally, the discordances and errors were largely
caused by an incomplete database. An extensive database is
critical for accurate identiﬁcation of Acinetobacter species by
MALDI-TOF MS.
In the present study, rpoB-sequence analysis assigned the
123 isolates to 13 species and could not reliably identify them
all (Fig. 1). In contrast, MALDI-TOF MS analysis assigned the
123 isolates to nine species and did not reliably identify them
all (Fig. 2). These results indicate that the discriminatory
power of MALDI-TOF MS is less than that of sequence analysis
of rpoB; however, the latter method is laborious and not
suitable for clinical laboratories. The main advantages of
MALDI-TOF MS are that species can be routinely identiﬁed
faster than sequencing rpoB, and the costs of consumables are
lower. Further, MALDI-TOF MS spectra may permit an
educated guess regarding the identity of an unknown.
The clinical relevance of Acinetobacter species as human
pathogens, other than A. baumannii, has not been sufﬁciently
assessed because of the scarcity of simple phenotypic tests
used in diagnostic laboratories. In the present study, 78.8%
(97/123) blood culture isolates were identiﬁed as 12 species of
Acinetobacter other than A. baumannii. Six of the 12 species,
A. ursingii, A. grimontii, A. johnsonii, A. junii, A. baylyi and A. ra-
dioresistens, were identiﬁed as A. lwofﬁi according to pheno-
typic tests, and the other six species, A. pittii, A. nosocomialis,
A. oleivorans, A. bereziniae, A. soli and Acinetobacter gen. sp.
14BJ, and A. baumannii were identiﬁed as A. baumannii by
phenotypic identiﬁcation. Surprisingly, the incidence of A. pittii
was high, 42/123 (34.1%), and exceeded that of A. baumannii,
22/123 (17.9%). Acinetobacter pittii is implicated in endocarditis
and can cause life-threatening infections, as do A. baumannii,
A. nosocomialis, A. johnsonii, A. lwofﬁi and A. beijerinckii [4,25,26].
The relatively high incidence of A. ursingii, which accounted for
15/123 (12.2%) of isolates, was unexpected but agrees with
observations from hospitals in the UK, the Netherlands and
Northern Ireland [4,27,28]. This organism infects the blood-
stream of hospitalized patients [7,11,29], and it has been
associated with a nosocomial outbreak of fatal bloodstream
infections in a neonatal intensive care unit [10]. Infections
caused by these organisms have different impacts on clinical
outcome and require different treatment and management
approaches [30]. It is therefore extremely important to
correctly identify Acinetobacter species, including non-A. bau-
mannii isolates.
In conclusion, MALDI-TOF MS is currently not adequate for
species-level identiﬁcation of Acinetobacter. However, our
present studies show that further expansion of the database
to include Acinetobacter species other than A. baumannii will
make MALDI-TOF MS an efﬁcient method for identiﬁcation of
nosocomial Acinetobacter species. Some Acinetobacter species
other than A. baumannii, particularly A. pittii, A. nosocomialis and
A. ursingii, have been associated with outbreaks [10,28],
suggesting that they may become an increasingly important
healthcare problem. We expect that MALDI-TOF MS will
provide a useful method for clinical laboratories to identify
Acinetobacter.
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